Keyhani A, Huh Y O, Jendiroba D, Pagliaro L, Cortez J, Pierce S, Pearlman M, Estey E, Kantarjian H, Freireich E J
Department of Leukemia, The University of Texas, M.D. Anderson Cancer Center, Houston 77030, USA.
Leuk Res. 2000 Feb;24(2):153-9. doi: 10.1016/s0145-2126(99)00147-2.
CD38 is expressed in acute lymphoblastic leukemia (ALL) and acute myelogenous leukemia (AML) blasts and its prognostic significance is unknown. We investigated CD38 expression in 304 AML and 138 ALL patients. CD38 was lower in AML-M3 compared to other FAB subtypes (5% vs. 41%; P < 0.001), but was similar among ALL subtypes (56.6%; P = 0.69). Ph + ALL and AML with t(15; 17) patients showed lower CD38 expression than the other cytogenetic groups. Overall survival favored AML and ALL patients with higher CD38 levels. Multivariate analysis revealed CD38 expression to be an independent outcome predictor in AML, but not in ALL.
CD38在急性淋巴细胞白血病（ALL）和急性髓细胞白血病（AML）原始细胞中表达，其预后意义尚不清楚。我们研究了304例AML患者和138例ALL患者的CD38表达情况。与其他FAB亚型相比，AML-M3中的CD38表达较低（5%对41%；P<0.001），但在ALL各亚型中相似（56.6%；P=0.69）。伴有t(15; 17)的Ph + ALL和AML患者的CD38表达低于其他细胞遗传学组。总体生存情况有利于CD38水平较高的AML和ALL患者。多变量分析显示，CD38表达是AML的独立预后预测指标，但在ALL中不是。
